Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Wednesday, 10 February 2021 09:15

Afshin Dowlati

Written by
Afshin Dowlati, MD is Professor of Medicine and Oncology at Case Western Reserve University and the Associate Director for Clinical Research at the Case Comprehensive Cancer Center. He directs the early phase therapeutics and thoracic oncology programs and University Hospitals Seidman Cancer Center. His laboratory research focuses on the biology of small cell lung cancer. His laboratory identified the YAP1 positive subgroup of SCLC in 2017. He is the recipient of the NCI Michaele Christian Oncology Development Lectureship award in 2012 for his efforts in early phase clinical trials.
Wednesday, 10 February 2021 09:15

Deborah Doroshow

Written by
Dr. Doroshow is Assistant Professor of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. She divides her clinical practice and research between the Early Phase Trials Unit, where she sees patients with a variety of solid tumors on phase 1 and 2 trials of novel agents, and the Center for Thoracic Oncology, where she sees patients with lung cancer. Her research focuses on the use of targeted therapies to treat cancer and examines the use of novel agents to target DNA damage and repair processes.
Wednesday, 10 February 2021 09:15

Jessica Donington

Written by
I am a general thoracic surgeon, a professor in the Department of Surgery, and chief of the section of Thoracic Surgery at the University of Chicago. My research has focused on the discovery and validation of diagnostic and prognostic biomarkers for thoracic malignancies. My clinical and interests focus on the diagnosis and treatment of non-small cell lung cancer. Areas of clinical expertise include the use of multimodality therapy for thoracic malignancies, treatment options for high risk patients with early stage lung cancer and cancer in women.
Wednesday, 10 February 2021 09:15

Max Diehn

Written by
Maximilian Diehn MD, PhD is the CRK Faculty Scholar and Associate Professor of Radiation Oncology at Stanford University. He is Vice Chair of Research of the Department of Radiation Oncology and Division Chief of Radiation and Cancer Biology. He received his Bachelor’s Degree in Biochemical Sciences from Harvard College and his M.D./Ph.D. in Biophysics from Stanford University. Dr. Diehn is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. His research program spans laboratory, translational, and clinical studies. His main areas of interest include liquid biopsies, lung cancer biology, and mechanisms of resistance to anti-cancer therapies including radiotherapy, immunotherapy, and targeted therapies. He has served on committees for a variety of national organizations including NCI, ASCO, AACR, ASTRO and RSNA and is a Scientific Editor for Cancer Discovery. Dr. Diehn has received funding from organizations such as the NIH, Department of Defense, and Stand Up To Cancer and he has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.
Wednesday, 10 February 2021 09:15

Ibiayi Dagogo-Jack

Written by
Dr. Ibiayi Dagogo-Jack received her bachelor’s degree from Vanderbilt University and her medical degree from the University of Chicago Pritzker School of Medicine. She trained in internal medicine at Brigham and Women’s Hospital. Following residency, she completed hematology/oncology fellowship in the combined Massachusetts General Hospital/Dana Farber Cancer Institute program. She is a medical oncologist at Massachusetts General Hospital where she specializes in thoracic cancers and conducts clinical and translational research. Her research focuses on understanding mechanisms underlying response and resistance to novel targeted therapies, investigating the role of non-invasive assays in molecular surveillance, and developing clinical trials that evaluate novel drug combinations in lung cancer and mesothelioma.
Wednesday, 10 February 2021 09:15

Sanja Dacic

Written by
Sanja Dacic is a professor of pathology in the Department of Pathology at the University of Pittsburgh , Director of Anatomic Pathology at UPMC Presbyterian Hospital and Director of Thoracic Pathology Center of Excellence . She is a member of the IASLC Pathology Committee.
Wednesday, 10 February 2021 09:15

Amy Cummings

Written by
Amy L. Cummings joined the thoracic oncology faculty at the David School of Medicine in 2020. Her interests include clinical trials, especially in early stage lung cancer, and applications of bioengineering to cancer genomics. She is part of the University of California Lung Cancer Consortium where she leads efforts around the use of clinical data.
Wednesday, 10 February 2021 09:15

Christine Culligan

Written by
Wednesday, 10 February 2021 09:15

Benjamin Creelan

Written by
Dr. Creelan earned his MD from Jefferson Medical College. He completed an Internal Medicine Residency at Thomas Jefferson University in the Department of Internal Medicine. Dr. Creelan then completed a Hematology Oncology Fellowship at the University of South Florida at Moffitt Cancer Center and a Master's Degree in Clinical and Translational Research through the National Institute of Health K30-sponsored SPOR program. Dr. Creelan focuses on translational and clinical research, specifically the development of new immune therapies, for the treatment of lung cancers. His research efforts aim to more effectively treat these cancers based on new insights into the biology of the disease.
Wednesday, 10 February 2021 09:15

Anne Chiang

Written by
I am a medical oncologist at Yale Cancer Center with a background in translational research in metastasis, as well as extensive experience in clinical practice in both academic and community settings. My specialty is in thoracic oncology and I am involved in clinical research protocols specific to our patients with lung cancer. I have a special interest in developing novel therapeutics for patients with non-small cell and small cell lung cancer, especially with an immune therapy and translational focus. In addition, I am the Associate Chief Medical Officer of Smilow Cancer Hospital and oversee operations, quality efforts, and clinical research in our Care Centers community locations. Other interests include quality improvement for cancer services.
Page 368 of 371